ArticleNature medicine2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Abstract read
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 2 pooled it
67.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 2 syntheses or guidelines pooled it, 240 citations in OpenAlex.
- Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.Nature medicine · 2024Pooled it
- Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.Nature communications · 2026Trial
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.Journal of hematology & oncology · 2024Trial
- Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.Human vaccines & immunotherapeutics · 2026Review
- A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy.Blood advances · 2026Review
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Rheumatologists' expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey.Rheumatology international · 2026Article
- Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy.Immuno-oncology technology · 2026Article
- Rewiring immunity with in vivo CAR T cell engineering.Nature cancer · 2026Review
- Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma.iScience · 2026Article
- [The risk and management strategies for second primary tumor after CAR-T cell therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.Blood neoplasia · 2026Article
- CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.Nature biomedical engineering · 2026Article
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- The TCR in CAR T cell therapy: use it or lose it?Cancer gene therapy · 2026Review
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Resetting autoimmune disease with CAR cell therapies.Nature medicine · 2026Review
- A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.Nature communications · 2026Article
- Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 2 institutions in 1 country.
Guido GhilardiLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Joseph A FraiettaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7900-8993
James N GersonLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Vivianna M Van DeerlinDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7400-9097
Jennifer J D MorrissetteDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Gabriel C CaponettiDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7763-2458
Luca ParuzzoLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Jaryse C HarrisDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Elise A ChongLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8895-1625
Sandra P Susanibar AdaniyaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0703-2518
Jakub SvobodaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Sunita D NastaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Ositadimma H UgwuanyiLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Daniel J LandsburgLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Eugenio FardellaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0007-0273-1316
Adam J WaxmanCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Emeline R ChongLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0324-5367
Vrutti PatelLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Raymone PajarilloLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Irina KulikovskayaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
David B LiebermanDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Adam D CohenCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0939-3843
Bruce L LevineCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-6971-8465
Edward A StadtmauerCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Noelle V FreyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Dan T VoglCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-2935-2566
Elizabeth O HexnerCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1125-4060
Stefan K BartaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
David L PorterCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Alfred L GarfallCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Stephen J SchusterLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-3376-8978
Carl H JuneCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0241-3557
Marco RuellaLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.ORCID 0000-0003-4301-5811
Hospital of the University of Pennsylvania · USUniversity of Pennsylvania · US
Funding
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8MMODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCERR37CA262362 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Marco Ruella · 2022 to 2026
$2.6MNCI NIH HHS P01 CA214278NCI NIH HHS R37 CA262362
Abstract
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8
Indexed as
Hematologic NeoplasmsLung NeoplasmsLymphoma, B-CellLymphoma, T-CellReceptors, Chimeric AntigenAntigens, CD19HumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellAntigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.